BSECompany UpdateMgmt Change30 Sept 2026
Piramal Pharma Limited
Piramal Pharma Limited has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left"> </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
Piramal Pharma Limited has informed BSE about the appointment of senior management personnel.
BSECompany UpdateMgmt Change30 Sept 2026
Piramal Pharma Limited
Piramal Pharma Limited has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left"> </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
Piramal Pharma Limited has informed BSE about the appointment of senior management personnel.
BSECompany UpdateMgmt Change30 Sept 2026
Piramal Pharma Limited
Piramal Pharma Limited has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left"> </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
Piramal Pharma Limited has informed BSE about the appointment of senior management personnel.
BSECompany UpdateMgmt Change30 Sept 2026
Piramal Pharma Limited
Piramal Pharma Limited has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left"> </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
Piramal Pharma Limited has informed BSE about the appointment of senior management personnel.
BSECompany UpdateMgmt Change30 Sept 2026
Piramal Pharma Limited
Piramal Pharma Limited has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left"> </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
Piramal Pharma Limited has informed BSE about the appointment of senior management personnel.
BSECompany UpdateMgmt Change30 Sept 2026
Piramal Pharma Limited
Piramal Pharma Limited has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left"> </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
Piramal Pharma Limited has informed BSE about the appointment of senior management personnel.
BSECompany UpdateMgmt Change30 Sept 2026
Piramal Pharma Limited
Piramal Pharma Limited has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left"> </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
Piramal Pharma Limited has informed BSE about the appointment of senior management personnel.
BSECompany UpdateMgmt Change30 Sept 2026
Piramal Pharma Limited
Piramal Pharma Limited has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left"> </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
Piramal Pharma Limited has informed BSE about the appointment of senior management personnel.
BSECompany UpdateMgmt Change30 Sept 2026
Piramal Pharma Limited
Piramal Pharma Limited has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%">
<tbody>
<tr><td width="250" class="TTRow_left"> </td><td class="TTRow_left"><b> Details</b></td></tr>
<tr><td ....
Piramal Pharma Limited has informed BSE about the appointment of senior management personnel.
BSECompany UpdateMgmt Change30 Sept 2026
Piramal Pharma Ltd
Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Changes in Senior Management Personnel.
Piramal Pharma Ltd has announced the retirement of Mr. Jeffrey Hampton, President and COO, Piramal Critical Care, and the appointment of Mr. Brian Guy as his successor, effective 19th October, 2026.
BSECompany UpdateOrder Win30 Sept 2026
Piramal Pharma Ltd
The Exchange has sought Clarification from Piramal Pharma Ltd with reference to the media report appearing on https://www.thehindubusinessline.com/ dated September 30, 2026 (Link: https://www.thehindubusinessline.com/brandhub/pr-release/ontario-contributes-17-million-investment-to-advance-life-sciences-innovation-at-piramal-pharmas-aurora-facility/article71526588.ece) titled "Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharmas Aurora Facility". ....
Piramal Pharma Ltd has received a clarification request from the exchange regarding a media report stating that Ontario has invested $1.7 million in Piramal Pharma's Aurora facility to advance life sciences innovation.
BSEInsider Trading / SAST29 Sept 2026
Piramal Pharma Ltd
Please refer the attachment.
Piramal Pharma Ltd has announced the closure of its trading window for all Designated Persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the half year ending September 30, 2026.
BSECompany UpdateRegulatory29 Sept 2026
Piramal Pharma Ltd
Please refer attachment.
Piramal Pharma Ltd has received a GST audit order from the Additional Commissioner, CGST & Central Excise, Mumbai East Commissionerate, demanding Rs. 4,06,03,220 in input tax credits and imposing a penalty of the same amount. The company intends to challenge the order and file an appeal.
BSECompany UpdateESG18 Sept 2026
Piramal Pharma Ltd
Please refer attached file
Piramal Pharma Ltd has been assigned an ESG rating of 67.1 (ESG Band: Leader) by Niche Ninety Nine Capability and Certifications (OPC) Private Limited, based on publicly available information.
BSECompany UpdateRegulatory14 Sept 2026
Piramal Pharma Ltd
Please refer attached file
Piramal Pharma Ltd has informed that the US FDA conducted a Good Manufacturing Practices (GMP) inspection of its Morpeth, UK facility from 3rd September, 2026 to 11th September, 2026, and issued a Form-483 with 7 observations related to enhancement in practices, procedures, and documentation.
BSECompany UpdateESG3 Sept 2026
Piramal Pharma Ltd
Please refer attached file
Piramal Pharma Ltd has received an ESG rating of 65 from NSE Sustainability Ratings and Analytics Ltd for FY 2025-26, marking an improvement over the previous score of 64.
BSEInsider Trading / SASTPledge26 Aug 2026
Piramal Pharma Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG
Deutsche Bank AG has made a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, regarding the creation of an encumbrance over 98,400,000 equity shares of Piramal Pharma Limited, constituting 7.39% of the total issued and paid-up share capital of the company.
BSECompany UpdateESG24 Aug 2026
Piramal Pharma Ltd
Please refer attached file
Piramal Pharma Ltd has released its Sustainability Report for FY2025-26, highlighting its progress in sustainability and responsible business practices.
BSECompany Update▲ PositiveM&A18 Aug 2026
Piramal Pharma Ltd
Please find enclosed intimation of acquisition of additional stake in Yapan Bio Private Limited
Piramal Pharma Ltd has acquired an additional 40.67% stake in Yapan Bio Private Limited, increasing its shareholding to 74.00% and making Yapan a subsidiary of the company.
BSEInsider Trading / SASTPledge18 Aug 2026
Piramal Pharma Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG
Piramal Pharma Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Deutsche Bank AG, Hong Kong Branch, regarding the release of encumbrance over 98,400,000 equity shares of Piramal Pharma Ltd, constituting 7.39% of the total issued and paid-up share capital of the company.